Detection of bladder cancer with aberrantly fucosylated ITGA3

Islam, Md. Rafiqul; Syed, Parvez; Dhondt, Bert; Gidwani, Kamlesh; Pettersson, Kim; Lamminmäki, Urpo; Leivo, Janne

doi:10.1016/j.ab.2021.114283

Cited by 12 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the ITGAs, ITGA3 in previous studies has been reported elevated in many cancers, including bladder cancer [21], thyroid carcinoma [22], non-small cell lung cancer [23], breast cancer [24], head and neck cancer [25], tongue cancer [26], and colorectal cancer [27]. However, there is only limited evidence regarding the expression of ITGA3 in pancreatic cancer.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Analysis on the Expression and Prognostic value of ITGA Family in Human Pancreatic Adenocarcinoma

Yang

Gao

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Pancreatic adenocarcinoma (PAAD) is the most common histological subtype of pancreatic cancer. Although dramatic progress has been made in multimodal therapies, PAAD still has a poor diagnosis and prognosis. The integrin α (ITGA) family genes play a fundamental role in different cancers. However, the potential values of ITGA family members in PAAD remain elusive. This study aimed to analyze the relationship between and ITGA family genes and PAAD.Methods: A variety of bioinformatic approaches, including UALCAN, GEPIA, Human Protein Atlas (HPA) database, Kaplan-Meier Plotter, cBioPortal, and STRING, which were used to analyze the potential roles of ITGA family members in human PAAD. The results were further verified in PAAD cell lines.Results: The transcriptional levels of ITGA 1/2/3/5/6/9/11 were up-regulated, whereas the expression of ITGA 4/8/10 were not obvious in patients with PAAD compared with that in normal pancreas. And a noticeable correlation was also discovered between the over-expressions of ITGA 2/3/5/6/11 and the clinical cancer stages of PAAD patients. Survival analysis revealed that the high mRNA expression of ITGA 2/3/5/6 and 11 were associated with overall survival (OS) in PAAD patients.Conclusion: Detection of ITGA genes has values in the diagnosis and prognosis of PAAD. ITGA 2/3/5/6/11 might serve as indicators of tumor stages of PAAD, while ITGA 2/5 may be new biomarkers for evaluating the prognosis of PAAD.

show abstract

Section: Discussionmentioning

confidence: 99%

Comprehensive Analysis on the Expression and Prognostic value of ITGA Family in Human Pancreatic Adenocarcinoma

Yang

Gao

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…ITGA3 serves as a cell adhesion molecule on the cell membrane. Previous researches have shown that the ITGA3 expression is associated with cancer development and metastasis, and that it binds to ECM proteins (26)(27)(28)(29). One study found that the high pancreatic expression of ITGA3 is linked to histological grade, T classification, the histological type of the pancreatic cancer, vital status, cancer stage, and recurrence (30).…”

Section: Gene Ratiomentioning

confidence: 99%

Development of a basement membrane gene signature and identification of the potential candidate therapeutic targets for pancreatic cancer

Lin¹,

Xu²,

Wang³

et al. 2023

Gland Surg

View full text Add to dashboard Cite

Background: Pancreatic cancer is a deadly cancer with a poor prognosis. In light of mounting evidence that basement membrane genes (BMGs) play a role in the development of cancer, we sought to examine the prognostic importance and role of BMGs in pancreatic ductal adenocarcinoma (PDAC) patients.Methods: BMGs were obtained from previous top research studies. The clinical and messenger ribonucleic acid expression data were retrieved from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) data sets, respectively. Cox regression and least absolute shrinkage and selection operator (LASSO) regression analyses were used for the PDAC risk modeling and gene identification. The Kaplan-Meier method was used to compare outcomes between the low-and high-risk groups. Finally, we analyzed small-molecule drugs that could be used to target BMGs for treatment using the Enrichr data set and validated the function of the tubulointerstitial nephritis antigen (TINAG) in pancreatic cancer.Results: We successfully constructed and validated a 7 BMG-based model to predict PDAC patient outcomes. Additionally, we discovered that 7 BMG-based model was an independent predictive factor for PDAC. According to our functional analysis, the majority of the signaling pathways enriched in BMGs were those connected to malignancy. Immune cell infiltration and immunological checkpoints were also linked to the BMG-based model. Further, we identified 5 small-molecule drugs that may be useful in treating PDAC patients. We also found that TINAG promoted cell proliferation in pancreatic cancer.Conclusions: Our study extended understandings of how BMGs work in PDAC. We identified a credible predictive biomarker for PDAC patients' survival.

show abstract

“…For this purpose, europium‐doped nanoparticles coated with lectin were designed and such assay based on ITGA3 can distinguish bladder cancer from BPH. 181 Another kind of nanoplatform for bladder cancer imaging is the application of quantum dots (QDs). 182 Overall, QDs are promising agents in cancer imaging and theranostic purposes owing to their small size and high biocompatibility.…”

Section: Nanoplatforms In Biosensing and Bioimagingmentioning

confidence: 99%

“…From unprocessed urine, integrin alpha‐3 (ITGA3) can be sensed by nanostructures. For this purpose, europium‐doped nanoparticles coated with lectin were designed and such assay based on ITGA3 can distinguish bladder cancer from BPH 181 . Another kind of nanoplatform for bladder cancer imaging is the application of quantum dots (QDs) 182 .…”

Section: Nanoplatforms In Biosensing and Bioimagingmentioning

confidence: 99%

(Nano)platforms in bladder cancer therapy: Challenges and opportunities

Ashrafizadeh

Zarrabi

Karimi‐Maleh

et al. 2022

Bioengineering & Transla Med

View full text Add to dashboard Cite

Urological cancers are among the most common malignancies around the world. In particular, bladder cancer severely threatens human health due to its aggressive and heterogeneous nature. Various therapeutic modalities have been considered for the treatment of bladder cancer although its prognosis remains unfavorable. It is perceived that treatment of bladder cancer depends on an interdisciplinary approach combining biology and engineering. The nanotechnological approaches have been introduced in the treatment of various cancers, especially bladder cancer. The current review aims to emphasize and highlight possible applications of nanomedicine in eradication of bladder tumor. Nanoparticles can improve efficacy of drugs in bladder cancer therapy through elevating their bioavailability. The potential of genetic tools such as siRNA and miRNA in gene expression regulation can be boosted using nanostructures by facilitating their internalization and accumulation at tumor sites and cells. Nanoparticles can provide photodynamic and photothermal therapy for ROS overgeneration and hyperthermia, respectively, in the suppression of bladder cancer. Furthermore, remodeling of tumor microenvironment and infiltration of immune cells for the purpose of immunotherapy are achieved through cargo‐loaded nanocarriers. Nanocarriers are mainly internalized in bladder tumor cells by endocytosis, and proper design of smart nanoparticles such as pH‐, redox‐, and light‐responsive nanocarriers is of importance for targeted tumor therapy. Bladder cancer biomarkers can be detected using nanoparticles for timely diagnosis of patients. Based on their accumulation at the tumor site, they can be employed for tumor imaging. The clinical translation and challenges are also covered in current review.

show abstract

Detection of bladder cancer with aberrantly fucosylated ITGA3

Cited by 12 publications

References 23 publications

Comprehensive Analysis on the Expression and Prognostic value of ITGA Family in Human Pancreatic Adenocarcinoma

Comprehensive Analysis on the Expression and Prognostic value of ITGA Family in Human Pancreatic Adenocarcinoma

Development of a basement membrane gene signature and identification of the potential candidate therapeutic targets for pancreatic cancer

(Nano)platforms in bladder cancer therapy: Challenges and opportunities

Contact Info

Product

Resources

About